Abstract: The novel compound provided by the invention is a higher carboxylic acid triester of adamantane triol such as adamamtane-1,3,5-triol tricaprylate not known in the prior art. The compound has a high kinematic viscosity at elevated temperatures despite the low pour point and has high thermal stability in an oxidizing atmosphere so that it is useful as an ingredient of a high-performance lubricating oil.

Abstract: Novel 1-azaspiro[4.4] lactams are produced by reaction of at least one hydroxy-containing primary amino compound with a 4-ketodiacid compound or a 1,6-dioxaspiro[4.4]lactone. Molar excesses of amion compound result in production of spirodilactams, while limited molar quantities of amino compound results in production of a spirolactam-lactone which reacts further with hydroxy-containing primary amino compound or with hydroxy-free primary amino compound to produce a spirodilactam. Certain of the spirolactams are useful as precursors for glycidyloxy derivatives which react with epoxy curing agents to form insoluble thermoset resins while others are useful as curing agents and yet others are converted to glycidyloxy derivatives useful as reactive diluents in epoxy resin applications.

Abstract: This invention concerns novel 2-hydroxy-5-alkylthio-1,3,4-thiadiazoles wherein the alkyl group may be substituted by hydroxy and phenoxy groups. The compounds are effective antiwear agents and antioxidants when incorporated into lubricating compositions.

Abstract: A ceramic sintered body comprising TiB.sub.2 as the principal component, 0.5 to 30 wt. % of SiC and 2 to 40 wt. % of ZrO.sub.2. In some cases ZrO.sub.2 includes stabilizers for tetragonal crystal, such as Y.sub.2 O.sub.3, MgO or CeO.sub.2. The sintered body has a dense structure where TiB.sub.2, ZrO.sub.2 and SiC uniformly disperse. ZrO.sub.2 is located at the grain boundary of TiB.sub.2, and inhibits the grain growth of TiB.sub.2 as well as improves the strength of the sintered body by binding it to TiB.sub.2 strongly. SiC is located not only at the grain boundary but also on the inside of both grains. Since the contract of SiC during cooling process of the sintered body is less than TiB.sub.2 and ZrO.sub.2, compressive stress is produced in SiC and around thereof. The sintered body is remarkably strengthened by the residual compressive stress, and simultaneously, the high fracture toughness is also achieved.

Abstract: A process for producing boron-containing ceramics such as boron carbide and boron nitride comprises pyrolyzing a blend of a precarbonaceous polymer such as polyacrylonitrile and a boron-containing polymer such as that formed by the reaction of a borane with a Lewis base. Pyrolyzation in an inert atmosphere yields boron carbide while pyrolyzation in a reactive gas burns away the precarbonaceous polymer and yields a ceramic comprising the reaction product of boron and the pyrolyzation gas. Boron nitride ceramics are formed by pyrolyzing the preceramic blend in ammonia.

Abstract: A novel complex of a class of tellurium and selenium compounds is disclosed, which is based on a complexing agent and the particular compound to be complexed.

Abstract: The 3-amino-4-ethylthio-quinoline of the Formula I ##STR1## and pharmaceutically acceptable acid addition salts thereof possess useful therapeutical properties. They exhibit a potent and highly selective anxiolytic and narcosis potentiating effect and are devoid of sedative and anti-convulsive effect. Consequently, the invention relates to pharmaceutical compositions comprising the compound of Formula I or a salt thereof as active agent.The invention also relates to a new and improved process for the preparation of the compound of Formula I.

Abstract: The new compounds of the general Formula I ##STR1## (wherein R.sub.1 stands for C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkinyl, C.sub.3-7 cycloalkyl or optionally substituted phenyl-(C.sub.1-4 alkyl);R.sub.2 represents hydrogen or C.sub.1-5 alkanoyl;X.sub.1 and X.sub.2 can be identical or different and each stands for hydrogen, halogen, trifluoromethyl or C.sub.1-4 alkoxy;(with the proviso that if R.sub.1 stands for ethyl, at least one of R.sub.2, X.sub.1 and X.sub.2 is different from hydrogen) and pharmaceutically acceptable acid additions salts possess valuable anxiolytic properties devoid of sedative effect and can be used in therapy.The compounds of the general Formula I can be prepared by methods known per se.

Abstract: The invention relates to new aminoacylates of glycerol acetal of the general formula I ##STR1## wherein R.sub.1 represents a substituted phenyl group or a group of the formula C.sub.m H.sub.2m+1, m being an integer of from 9 to 25,R.sub.2 represents a hydrogen atom, a phenyl group or a group of the formula C.sub.n H.sub.2n+1, n being an integer of from 1 to 10,p is a integer of from 3 to 10, ##STR2## represents a nitrogen containing heterocyclic group and X.sup..crclbar. means a pharmaceutically acceptable anion to a preparation process of said compounds and to therapeutic compositions of matter containing the same.

Abstract: An antibacterial 7beta-(carboxyalkenoyl)amino-3-cephem-4-carboxylic acid represented by the following formula: ##STR1## (wherein R is aryl or a heterocyclic group;R.sup.1 is hydrogen or halogen;R.sup.2 is a single bond, alkylene, or thiaalkylene;R.sup.3 is a hydrogen atom or carboxy modifying group;R.sup.4 is hydrogen or methoxy;R.sup.5 is hydrogen or a 3-substituent of cephalosporins;R.sup.6 is a hydrogen atom or carboxy modifying group; andX is oxygen, sulfur, or sulfinyl)a pharmaceutical composition containing the same, and a method for treating a bacterial infection with the same.

Abstract: The invention relates to ceramic articles.It relates to an article made of ceramic material produced by fusing and casting in a mold a composition based on alumina, zirconia, silica and an alkali metal oxide, said article consisting of crystalline corundum and zirconia phases and of a vitreous phase, said zirconia being substantially in monoclinic form from the core to the skin of said article, and having, in at least one of its parts, a thickness lower than or equal to 30 mm and being intended for an application where mechanical strength and/or abrasion resistance are of primary importance, said composition consisting essentially, in % by weight based on the oxides, of:______________________________________ Al.sub.2 O.sub.3 40-75 ZrO.sub.2 20-55 SiO.sub.2 5-20 Na.sub.2 O 0-2.7 K.sub.2 O 0.15-4.25 Fe.sub.2 O.sub.3 + TiO.sub.2 + CaO + MgO 0-2, ______________________________________with the condition that the weight ratio ##EQU1## is between 0.07 and 0.14 inclusive.

Abstract: Preceramic compositions which have particular utility in providing protective ceramic coatings having low moisture sensitivity on carbon/carbon composites, graphite, carbon fibers, and other normally oxidizable materials are prepared by dispersing about 0.1-1.0 part by weight of a Group IIA metal salt with an organoborosilazane polymer solution obtained by reacting about 0.25-20 parts by weight of a trialkoxy-, triaryloxy-, or tri(arylalkoxy)boroxine with one part by weight of a polysilazane in an organic solvent and, if desired, heating the dispersion to convert it to a solution.

Abstract: A method for producing a 2,4-dihydroxyquinoline derivative of the formula: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom, a lower alkyl group, a lower alkoxy group or a halogen atom, and its tautomer, which comprises cyclizing an aryl malonic acid amide ester derivative of the formula: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined above, and R.sup.5 is a lower alkyl group, by means of polyphosphoric acid.

Abstract: Disclosed are novel compounds derived from 2,5-dimercapto-1,3,4-thiadiazole and one or two moles of polyolefin having 5 to 400 carbon atoms. Furthermore, the 5-position of the 2-mercapto-1,3,4-thiadiazole may be substituted by alkylthio, 2-hydroxyalkylthio, amino or hydroxy group. The compounds are effective dispersants, antiwear agents and antioxidants when incorporated into lubricating compositions.

Abstract: A synthetic lubricant comprising a compound represented by the following general formula (I): ##STR1## wherein Rf and Rf' represent a fluorine-containing polyoxyalkylene group, X and X' a polar group, Y of one or more selected from the group consisting of methylene, ethylene, propylene, oxygen, ketone, imino, sulfon and sulfur or no atom or group, and n an integer of 0 to 5, and a magnetic recording medium coated with this lubricant.

Abstract: Novel epoxyalkoxy-containing [4.4] spirodilactams having ring nitrogen atoms in the 1- and the 6- ring positions and having a substituent on each ring nitrogen atom, at least one of which substituents contains an epoxyalkyl moiety. Such epoxy compounds are produced by reaction of a 1-halo-2,3-epoxyalkane and the corresponding hydroxy-containing spirodilactam followed by treatment with strong base.

Abstract: Processes and intermediates for preparing 1,4-diazabicyclo[3.2.2.]nonane including a process for the preparation of a compound of the formula ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkyl substituted with 1 to 6 halo groups; and R.sup.2 is hydrogen, naphthoyl, substituted naphthoyl, benzyl, substituted benzyl, benzoyl or substituted benzoyl, wherein each of said substituted naphthoyl, substituted benzyl, and substituted benzoyl is substituted with one to three substituents selected from the group consisting of halo, C.sub.1 -C.sub.4 alkoxy and C.sub.1 -C.sub.4 alkyl, comprising reacting a compound of the formula ##STR2## wherein R.sup.1 and R.sup.3 are independently selected from C.sub.1 -C.sub.4 alkyl and C.sub.1 -C.sub.4 alkyl substituted with 1 to 6 halo groups with an alkyl stannane or a trialkyl aluminum and, if desired, reacting the resulting compound of the formula III wherein R.sup.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 represent the structure ##STR2## R.sup.3 and R.sup.4 are hydrogen, or R.sup.3 and R.sup.4 taken together form a 3-5 membered saturated carbocyclic ring;R.sup.5 and R.sup.6 are hydrogen, or R.sup.5 and R.sup.6 taken together form a 3-6 membered carbocyclic ring or a cyclobutenyl ring; with the proviso that when R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are hydrogen, n is other than zero;m is 2-4;n is 0-4;X is lower alkylene, vinylene or O;R.sup.7 is unsubstituted or substituted phenyl, 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl or 3-pyridazinyl; where the substituents are selected from the group lower alkyl, lower alkoxy, halo, cyano, nitro and trifluoromethyl;and the pharmaceutically acceptable salts thereof and their use as antipsychotic/anxiolytic agents having a low liability for extrapyramidal side effects.

Abstract: The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20.degree. to 50.degree. C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA.

Abstract: A galenic formulations are disclosed with programmed release, to be administered orally containing as the active ingredient a compound having antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid, and pharmaceutically acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action and reach the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow therapeutic coverage until subsequent administration. The therapeutic coverage can even last twenty-four hours. Thus, the new galenic formulations object of the present invention are suitable for administration one a day.